- Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Olema Oncology to Participate in Upcoming Investor Conferences in June
- Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
- Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
- Olema Oncology to Participate in Upcoming Investor Conferences in May
- Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
- Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
- Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
- Olema Oncology to Participate in Upcoming Investor Conferences
More ▼
Key statistics
On Friday, Olema Pharmaceuticals Inc (OLMA:NSQ) closed at 10.67, 37.15% above the 52 week low of 7.78 set on Jul 31, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.65 |
---|---|
High | 10.73 |
Low | 10.29 |
Bid | 10.01 |
Offer | 10.74 |
Previous close | 10.67 |
Average volume | 941.25k |
---|---|
Shares outstanding | 55.93m |
Free float | 53.80m |
P/E (TTM) | -- |
Market cap | 596.81m USD |
EPS (TTM) | -2.02 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:00 BST.
More ▼